Edgewise Therapeutics(EWTX)

Focus: Edgewise Therapeutics is a publicly traded biotech company focused on small-molecule therapeutics for musculoskeletal diseases, including rare muscular dystrophies and cardiomyopathy. The company operates as a clinical-stage biotech with a lean operational footprint.

Musculoskeletal

Profile data last refreshed 16h ago · AI intelligence enriched 3w ago

Funding Stage

PUBLIC

Open Jobs

17+3 this month

Stable — net +3 jobs in 30d

5 added, 2 removed. Backfill posture.

Should You Work at Edgewise Therapeutics?

AI assessment

Attractive for early-clinical scientists and regulatory professionals betting on rare disease validation, but high financial risk requires tolerance for burn rate and dilution.

Why Work Here

Public company with ticker (EWTX) offering equity liquidity and capital market visibility, reducing cash-runway anxiety common at pre-revenue biotechs.

Data completeness

5/9 — Partial

Company HealthSolid

Pipeline

Early-stage

18 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Defining Endpoints in Becker Muscular Dystrophy

Becker Muscular Dystrophy

N/A

Clinical Trials (1)

NCT05257473Defining Endpoints in Becker Muscular Dystrophy

N/A

Help build intelligence for Edgewise Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused pipeline in unmet musculoskeletal disease space with lead program Sevasemten in Phase 2 for muscular dystrophies, a high-value regulatory niche.

Active hiring across clinical, medical affairs, and pharmacology roles (14 open positions) signals near-term clinical expansion and trial acceleration.

Watch Out For

Severe cash burn: $100M net loss on only $91M R&D spend; cash position declined 51% YoY ($86M→$42M), creating <6-month runway pressure.
Pipeline is pre-commercial: no marketed products, no revenue, and only 4 Phase 2 programs—regulatory catalysts are 2+ years away.

Generated by Claude from Edgewise Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Fast Troponin as a Biomarker to Assess Exercise-induced Muscle Damage in Muscle Diseases

Becker Muscular Dystrophy

N/A

Clinical Trials (1)

NCT04349566Fast Troponin as a Biomarker to Assess Exercise-induced Muscle Damage in Muscle Diseases

N/A

EDG-7500

Healthy Subjects

PHASE_1

Clinical Trials (1)

NCT06011317A Study of EDG-7500 in Healthy Adults

Phase 1